期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米基础化疗方案治疗初发合并肾功能不全的多发性骨髓瘤患者的进展 被引量：5

原文传递
导出
摘要 约有20％～40％的多发性骨髓瘤（MM）患者在疾病发展的某个阶段会合并肾功能不全，这些伴有肾功能不全的患者对于传统化疗反应差，早期死亡率高，生存时间明显低于未伴有肾功能不全的患者。以硼替佐米为基础的化疗方案已经在MM的治疗中取得了令人瞩目的疗效，但是在初发合并。肾功能不全的MM患者中应用的情况报道较少。此化疗方案对于存在肾功能损害的初发MM患者是安全有效的。本文对初发合并肾功能不全的MM患者硼替佐米基础化疗方案的进展作一综述。
作者 王岩(综述) 黄仲夏(审校)
机构地区 首都医科大学附属北京朝阳医院血液肿瘤科
出处 《国际输血及血液学杂志》 CAS 2011年第5期335-337,共3页 International Journal of Blood Transfusion and Hematology
关键词 多发性骨髓瘤 肾功能不全 硼替佐米
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献20

  • 1Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007,48(2) :337-341.
  • 2Chanan-KhanAA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study. Blood,2007, 109 (6):2604-2606.
  • 3Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone- containing regimes and the impact of novel agents. Haematologica, 2007, 92(4):546-549.
  • 4Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention with new insights from in vitro and in vivo models of renal injury. Am J Nephrol,2009, 22(1) :17-28.
  • 5Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol,2010, 84(3) :223-228.
  • 6Dimopoulos MA, Roussou M, Gavriatopoulou M, et aI. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive faetors. Clin Lymphoma Myeloma, 2009, 9 (4) : 302- 306.
  • 7Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can he reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma:results of a phase Ⅱ study. J Clin Oncol,2010, 28(30) :4635-4641.
  • 8Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res, 2010, 34(10):1395- 1397.
  • 9Li J, Zhou DB, Jiao L, et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma, 2009,9 (5) : 394-398.
  • 10Qayum A, Aleem A, AI Diab AR, et al. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl, 2010, 21 (1) : 63-68.

同被引文献81

  • 1李娟.难治、复发多发性骨髓瘤治疗进展[J].国际输血及血液学杂志,2007,30(4):291-296. 被引量：4
  • 2Stomp6r T, Zab ocki M, Pankrac K. Renal involvement in muhiplemyeloma. Pol Arch Med Wewn, 2012, 122: 443-.
  • 3Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant, 2012, 27: 3823-3828.
  • 4Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol, 2011, 22: 1129-1136.
  • 5Hutchison CA, Basnayake K, CockweU P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol, 2009, 5: 621-628.
  • 6Davenport A, Merlini G. Myeloma kidney: advances in molecar mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transplant, 2012, 27._ 3713-3718.
  • 7Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention--with new insights fl"om in vitro and in vivo models of renal injury. J Nephrol, 2009, 22: 17-28.
  • 8Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emergevia endothelial-to-mesenchymal transition. J Am Soc Nephrol, 2008, 19: 2282-2287.
  • 9Strutz FM. EMT and proteinuria as progression factors. Kidney Int, 2009, 75: 475-481.
  • 10Liu M, Liu YZ, Feng Y, et al. Novel evidence demonstrates that epithelial- mesenchymal transition contributes to nephrolithiasis-induced renal fibrosis. J Surg Res, 2012, Epub ahead of print.

引证文献5

二级引证文献6

国际输血及血液学杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部